r/rxrx

Institutional "Whale" Accumulation

While insiders are liquidating for taxes, the largest asset managers in the world are increasing their conviction:

• Vanguard Group: In their most recent filing update, Vanguard increased its position by +18.1%, now holding approximately 47.6 million shares.

• BlackRock: As noted earlier, BlackRock recently filed a 7.2% stake, signaling they are using the current $3.00–$3.50 price range to build a long-term position.

• Pictet Asset Management: Reported a massive +65.5% increase in their position this quarter, one of the most aggressive institutional "buy" signals in the TechBio sector. 

3rd quarter of 2025 the CFO said by years end (2026) they would have $100,000,000 in collaborations! To date they only have $41,000,000 and now he says 12-18 months is the new timeline! Stop hyping up this stock when in reality RXRX probably won’t do this amount in the timeline suggested! Too much hype!! Let Najat Khan do her thing and bring respectability back to RXRX! After the quarter earnings just bring out the CEO and the CMO to discuss the quarter! Plus all you insiders keep on selling your shares! Not A Good Sign…

Wait until the earnings come out before we load up on these officers of the company!

On May 7, 2026, analyst Gil Blum from Needham maintained a 'Buy' rating for Recursion Pharmaceuticals (RXRX). The price target remains unchanged at $8.00, reflecting the analyst's confidence in the company's performance.

• GF Value™ verdict: $5.12 vs Current Price $3.27 = 36.1% undervalued
• GF Score™: 75/100, indicating strong potential for long-term returns
• Key financial signal: Insider activity shows $1.4M in sales over the last 3 months

Source: https://www.gurufocus.com/news/8843812/rxrx-reiterates-by-needham-price-target-maintained-at-800

Recursion remains one of the most watched AI-biotech stories: not because it has already proven a commercial model, but because Q1 2026 shifts the focus from technology narrative to clinical execution, cash discipline and regulatory path clarity.

All you analysts that have projected $20 million in earnings should be disbarred! You know RXRX doesn’t have hardly any monies coming in and yet you project ridiculously high numbers of revenue! RXRX will be lucky to do $8 million! We investors want new analysts that know what they’re talking about! U always optimistic and WRONG! Get with it

Yesterday (April 30, 2026), Recursion’s 2025 Annual Report was released via the SEC Filings section and on Nasdaq.

For those who have been following the story closely, much of what the report outlines will feel familiar. Several of the key points and conclusions had already surfaced in earlier discussions—some of which I explored in a previous (admittedly more spirited) post:
https://www.reddit.com/r/rxrx/comments/1shk14d/enthusiasm_and_cheering_are_fine_but_are_we_being/

One detail that now appears clearer, however, is the timing of the $300M dilution. What had initially been somewhat ambiguous is now explicit: the process effectively began in February 2026, as stated in the report (page 74), with the company entering into an at-the-market offering agreement for up to $300 million in Class A common stock:

'In February 2026, we entered into a sales agreement for an at-the-market offering for the sale of up to $300 million in Class A common stock (see “Part II - Item 9B - Other Information” for further details). '

On a more strategic note, the decision to establish a New York office aimed at attracting AI talent is understandable and, in many ways, sensible. That said, one might still wonder whether Silicon Valley—despite its costs and chaos—remains the more “natural habitat” for this kind of recruitment. Then again, perhaps proximity to talent now outweighs proximity to venture capital clichés.

Beyond that, the broader picture remains largely unchanged: development timelines are long, very long, and operating expenses, while slightly decreasing, remain structurally high.

Revenues, for now, continue to rely on collaborations rather than product commercialization.

Personally, I have no particular attachment to being “right.” If anything, being proven wrong would likely be the most bullish signal available. That said, the core observations from my earlier analysis still appear to hold true:
https://www.reddit.com/r/rxrx/comments/1shk14d/enthusiasm_and_cheering_are_fine_but_are_we_being/

And finally, to reiterate one small but telling point: the New York expansion is clearly intended to strengthen access to AI and Bio-AI talent. Whether that proves more effective than a Silicon Valley base remains an open question—but at the very least, it spares employees from having to justify Bay Area rent prices at dinner parties.

Luca

Document Source (PDF Only): https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&ref=320002682&type=PDF&symbol=RXRX&cdn=63b2c8ee19636101f8252d3869663b33&companyName=Recursion+Pharmaceuticals+Inc.&formType=ARS&formDescription=Annual+Report+to+Security+Holders&dateFiled=2026-04-30